Lynette Moon, PA
Physician Assistant · Indianapolis, INNPI 1598131278
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 414 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. Among physician assistant clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 414 payments — averaging $18.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Johnson & Johnson$796
- Sanofi$384
- Gilead$352
- plus $2K from 24 others
What the payments were for
- Food & beverage$7,63498%
- Education$1352%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 98 | $1,576 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 70 | $1,351 |
| Takeda Pharmaceuticals U.S.A., Inc. | 57 | $1,062 |
| Johnson & Johnson | 33 | $796 |
| Sanofi | 11 | $384 |
| Gilead | 18 | $352 |
| Ardelyx, Inc. | 14 | $228 |
| Aimmune Therapeutics, Inc. | 12 | $228 |
| Bristol Myers Squibb | 13 | $203 |
| Madrigal Pharmaceuticals | 16 | $194 |
| Pfizer | 10 | $167 |
| Lilly USA, LLC | 7 | $155 |
| Celltrion USA Inc. | 8 | $153 |
| Nestle Healthcare Nutrition Inc. | 8 | $136 |
| Regeneron Healthcare Solutions, Inc. | 5 | $105 |
| QOL Medical, LLC | 5 | $96 |
| Ironwood Pharmaceuticals, Inc | 5 | $94 |
| Ferring Pharmaceuticals Inc. | 4 | $73 |
| Phathom Pharmaceuticals, Inc. | 3 | $68 |
| Braintree Laboratories, Inc. | 2 | $67 |
| Ipsen Biopharmaceuticals, Inc | 3 | $61 |
| Merck | 2 | $47 |
| Intercept Pharmaceuticals, Inc. | 3 | $42 |
| Novo Nordisk | 1 | $26 |
| Tersera Therapeutics LLC | 1 | $23 |
| UCB, Inc. | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $15 |
| Alfasigma USA, Inc. | 1 | $15 |
| Redhill Biopharma Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,769 in reported general payments places this provider in the 95th percentile of 1,955 physician assistant providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 12 | $80,754 |
| LinzessLinaclotide | 64 | $50,770 |
| Mesalamine | 17 | $17,895 |
| Lubiprostone | 38 | $4,580 |
| Colestipol Hcl | 29 | $3,809 |
| Esomeprazole Magnesium | 20 | $2,655 |
| Pantoprazole Sodium | 124 | $1,434 |
| Omeprazole | 148 | $1,430 |
| Famotidine | 126 | $1,024 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 36 | $692 |
| Sucralfate | 24 | $690 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 13 | $515 |
| Dicyclomine Hcl | 35 | $461 |
| Azathioprine | 15 | $457 |
| Ondansetron OdtOndansetron | 11 | $320 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $1,576 | $50,77064 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,955 physician assistant providers in Indiana.
Other physician assistant in Indianapolis
- Andrew NordIndianapolis$47K
- Qun Ming ZhangIndianapolis$28K
- Lindsay YoderIndianapolis$21K
- Mackenzie LawsonIndianapolis$15K
- Christina RaceIndianapolis$13K
- Zara BogenschutzIndianapolis$12K
- Ashley WorthingtonIndianapolis$11K
- Madison MaloofIndianapolis$10K
- Michaela WehrIndianapolis$10K
- Ryan RosebroughIndianapolis$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.